Economic burden of non-transfusion-dependent thalassemia in the United States
Patients with NTDT in the United States, including those with α- and β-thalassemia, have significantly higher all-cause HCRU and costs vs. matched controls. There is a need for effective treatment options to reduce the healthcare burden of NTDT and improve patient outcomes.
Authors
- Amey Rane
- Louise Lombard
- Arielle L. Langer (ORCID: https://orcid.org/0000-0002-0301-7073)
- Keely Gilroy
- Sujit Sheth
- Carolyn R. Lew (ORCID: https://orcid.org/0000-0003-1115-0672)
- Jing Zhao
Institutions
- Brigham and Women's Hospital (US)
- Harvard University (US)
- Cornell University (US)
- Agios Pharmaceuticals (United States) (US)
- Weill Cornell Medical College in Qatar (QA)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2026-02-03
- DOI
- https://doi.org/10.1080/13696998.2026.2618930
- Primary Topic
- Hemoglobinopathies and Related Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00